Sotera Health Co (SHC) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Sotera Health Co (SHC) stock forecast summary
Our AI ranks Sotera Health Co outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Sotera Health Co is a mid-cap company with a market capitalization of $5.06B. It ranks number 3 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for SHC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SHC included.
Follow SHC freeSHC price chart and AI forecast
How SHC ranks among 4012 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Sotera Health Co (SHC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | SHC | Rank |
|---|---|---|
| Market Cap | $5.06B | 3/11 |
| P/E Ratio | 30.95x | 1/5 |
| P/B Ratio | 7.60x | 1/7 |
| EPS | $0.43 | – |
| Book Value/Share | $2.33 | – |
| Revenue/Share | $4.26 | – |
| FCF/Share | $0.39 | – |
Profitability & Margins
| Metric | SHC | Rank |
|---|---|---|
| ROE | 24.6% | 1/7 |
| ROA | 4.9% | 4/10 |
| Gross Margin | 55.0% | 4/6 |
| Net Margin | 13.4% | 2/10 |
| EBT Margin | 21.7% | 1/10 |
| Tax Rate | 38.1% | – |
Financial Health
| Metric | SHC | Rank |
|---|---|---|
| Current Ratio | 2.80x | 2/11 |
| Quick Ratio | 2.55x | 1/5 |
| D/E Ratio | 3.97x | 3/9 |
| Financial Leverage | 4.97x | 3/9 |
| Interest Coverage | 2.4x | 8/12 |
| Working Capital | $415M | 2/11 |
Cash Flow
| Metric | SHC | Rank |
|---|---|---|
| Operating Cash Flow | $292M | 3/11 |
| Free Cash Flow | $113M | 3/7 |
| Capital Spending | -$179M | 6/7 |
| OCF Growth YoY | 9.8% | 3/7 |
| FCF Growth YoY | 0.0% | 2/5 |
| FCF/Sales | 9.3% | 5/7 |
| CapEx/Sales | 14.8% | 1/7 |
Operational Efficiency
| Metric | SHC | Rank |
|---|---|---|
| Asset Turnover | 0.37x | 8/9 |
| Receivables Turnover | 8.1x | 4/9 |
| Inventory Turnover | 9.7x | – |
| Fixed Assets Turnover | 1.0x | 7/8 |
| Days Sales Outstanding | 45 days | 6/9 |
| Days Inventory | 38 days | – |
| Payables Period | 67 days | 4/5 |
| Cash Conversion Cycle | 15 days | – |
Income Statement
| Metric | SHC | Rank |
|---|---|---|
| Total Revenue | $1.22B | 4/9 |
| Net Income | $163M | 2/10 |
| SG&A Expense | $257M | 3/6 |
| Cost of Goods Sold | $548M | 3/8 |
Dividend & Shareholder Information
| Metric | SHC | Rank |
|---|---|---|
| Shares Outstanding | 285M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $646M | 19.5% of assets |
| Cash & Short-term Investments | $357M | 10.8% of assets |
| Accounts Receivable | $151M | 4.6% of assets |
| Inventory | $56M | 1.7% of assets |
| Total Liabilities | $2.64B | 79.9% of assets |
| Short-term Debt | $130M | 3.9% of assets |
SHC quarterly financials and insider trading
Sotera Health Co (SHC) industry peers
Companies classified under the same SEC industry code as Sotera Health Co (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SHC Sotera Health Co | ▼ | $5.06B |
| DVA Davita Inc. | ▲ | $11.53B |
| FMS Fresenius Medical Care Ag | ▼ | $6.02B |
| PGNY Progyny, Inc. | ▶ | $2.14B |
| AGL Agilon Health, Inc. | ▶ | $1.47B |
| VMD Viemed Healthcare, Inc. | ▲ | $369M |
| PARK Park Dental Partners, Inc. | ▶ | $90M |
| MRAI Marpai, Inc. | ▲ | $86M |
| CCEL Cryo Cell International Inc | ▲ | $33M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▶ | $7M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where SHC sits on the market map
Sotera Health Co (SHC) stock news
Loading...
Sotera Health Co (SHC) stock forecast FAQ
What is the Sotera Health Co (SHC) stock forecast?
Our AI ranks Sotera Health Co outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Sotera Health Co stock predictions?
A per-ticker accuracy statistic for SHC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Sotera Health Co forecasts updated?
Sotera Health Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Sotera Health Co's industry peers?
13 issuers in our coverage, SHC included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Davita Inc. (DVA), Fresenius Medical Care Ag (FMS), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD), Park Dental Partners, Inc. (PARK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.